On June 23rd, ANGELALIGN TECHNOLOGY INC. was awarded the “Most Honored Company” in Institutional Investor’s poll of 2022 All-Asia Executive Team. Ranked second overall in the category of Health Care & Pharmaceuticals, the company was at the second place in other four individual awards, namely “Best CEO”, “Best IR Professional”, “IR Program”, and “ESG”.

This year, a total of 1,612 listed companies across 18 sectors were nominated in the Institutional Investor 2022 All-Asia Executive Team Poll. Though it was the first time that ANGELALIGN TECHNOLOGY INC. was rated in the poll since its listing on the Hong Kong Stock Exchange in June 2021, the company received various awards from the Institutional Investor, which highlights the capital market’s high recognition on ANGELALIGN TECHNOLOGY INC. in corporate governance and investor relations etc.

ANGELALIGN TECHNOLOGY INC. is a leading clear aligner treatment solution provider in China. Since established, the Company has been immersing itself in “digital orthodontics” by focusing on the needs of dental professionals and clinical scenarios. It has been developing industry-leading and proprietary technological capabilities in five disciplinary fields, including clinical stomatology, biomechanics, material science, computer science and intelligent manufacturing technology. With the help of continuously refined products and technological services, the company has been empowering doctors comprehensively. In face of an array of challenges from COVID-19 and weak consumption etc over the past year, ANGELALIGN TECHNOLOGY INC. maintained an agile forecasting on the market and quickly enforced coping strategies to seize opportunities at its best while devoted to long-term business growth. The Company achieved approximately 183,200 case shipments, served around 25,000 dental professionals throughout the year, gaining high-quality growth and breakthroughs, and further consolidating its leading position…